Ross Osborn

Stock Analyst at Cantor Fitzgerald

(0)
# 3679
Out of 5,287 analysts
111
Total ratings
37.63%
Success rate
-0.21%
Average return
24 Stocks
Name Action Price Target Current % Upside Ratings Updated
Elutia
Reiterates: Overweight
8 8
2.84 181.69% 10 Mar 7, 2025
Axogen
Reiterates: Overweight
24 24
18.14 32.3% 3 Mar 5, 2025
NeuroPace
Maintains: Overweight
19 20
12.37 61.68% 5 Mar 5, 2025
MiMedx Group
Reiterates: Overweight
13 13
8.1 60.49% 3 Feb 27, 2025
SI-BONE
Reiterates: Overweight
25 25
14.83 68.58% 8 Feb 25, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
4 4
1.55 158.06% 4 Feb 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
44 44
35.41 24.26% 5 Jan 23, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
9 9
4.09 120.05% 7 Jan 16, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
8 8
4.03 98.51% 5 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
9
5.08 77.17% 1 Jan 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
21 21
9.32 125.32% 10 Dec 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
11 12
6.12 96.08% 10 Dec 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
3 2
1.5 33.33% 4 Nov 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
16 16
11.22 42.6% 4 Nov 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
14 14
12.75 9.8% 2 Oct 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
96
86.09 11.51% 1 Oct 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
4 4
1.32 165.15% 5 Aug 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
3 3
0.57 338.6% 3 May 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
n/a
n/a n/a 7 Apr 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
4 4
0.09 3566.67% 5 Apr 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
5 5
5.41 -7.58% 2 Mar 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 3 Nov 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
9
0.8 976.25% 2 Aug 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Overweight
27 21
n/a n/a 2 Apr 22, 2022